AMX3009

AMX3009 is an orally administered small molecule inhibitor targeting both the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ERBB2). It is being developed primarily for the treatment of cancers with rare EGFR mutations, such as locally advanced or metastatic non-small cell lung cancer (NSCLC), and has also been studied in HER2-positive advanced solid tumors. The drug acts as a dual EGFR/HER2 antagonist, aiming to inhibit tumor cell proliferation driven by these pathways. Clinical trials have focused on evaluating its safety, tolerability, pharmacokinetics, and efficacy in these patient populations[1][2][3].

Other names

AMX-3009 MaleateAMX3009 MaleateAMX 3009 Maleate